In a post-hoc analysis of the DISCOVER-2 trial, guselkumab showed significant long-term improvement in joint symptoms, spinal pain, and skin clearance in biologic-naive patients with active psoriatic arthritis (PsA). By week 100, patients receiving guselkumab every 4 or 8 weeks experienced reductions in joint counts, improvement in skin psoriasis symptoms, and resolution of enthesitis and dactylitis. A considerable proportion of patients achieved treatment targets for low disease activity and minimal disease activity. No cases of inflammatory bowel disease were reported, with one case of uveitis in the 8-week dosing group. The authors suggest guselkumab as an important treatment option for addressing key therapeutic goals in PsA.
Source link
Guselkumab Provides Long-Term Relief From PsA Symptoms
